Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31138818 | 1.00 | CD274 (0.52) | CD274NPC1RAB9AEPHX2POLB | |
| SCHEMBL32665265 | 0.86 | OPRM1 (0.50) | NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL16731692 | 0.84 | NPSR1 (0.58) | NPC1RAB9APOLBKMT2AMEN1 | |
| SCHEMBL3503130 | 0.84 | GAA (0.61) | NPC1RAB9AEPHX2POLBKMT2A | |
| SCHEMBL15393707 | 0.80 | KMT2A (0.61) | KMT2AMEN1 | |
| SCHEMBL32665129 | 0.79 | GLA (0.43) | NPC1RAB9APOLBKMT2AMEN1 | |
| SCHEMBL19422367 | 0.77 | CD274 (0.46) | CD274NPC1RAB9AEPHX2POLB | |
| SCHEMBL32665387 | 0.77 | OPRM1 (0.52) | NPC1RAB9A | |
| SCHEMBL16868846 | 0.76 | L3MBTL1 (0.57) | NPC1RAB9APOLBKMT2AMEN1 | |
| SCHEMBL29444954 | 0.75 | NPC1 (0.55) | NPC1RAB9AEPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018048856-A1 | METHOD FOR EFFICIENT RADIOLABELING OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-15 | — | — | WO | claimed |
| CN-118647632-A | Fusion proteins comprising EGFR binding and masking domains | 齐托克斯治疗公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2018048856-A1 | METHOD FOR EFFICIENT RADIOLABELING OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8545809-B2 | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules | IMMUNOMEDICS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120134920-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | IMMUNOMEDICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134920-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, FCGRT, PAICS | CD274 2557/4885NPC1 4001/4885RAB9A 790/4885 |
| US-20140017168-A1 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules | F13B, FCGRT, PAICS | CD274 2557/4885NPC1 4001/4885RAB9A 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.